S 4348

FDASLA Act of 2022

Congress: 117 (2021–2023, Ended)
Chamber: Senate
Policy Area: Health
Introduced: May 26, 2022
Current Status: Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.
Latest Action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 444. (Jul 13, 2022)
Official Text: https://www.congress.gov/bill/117th-congress/senate-bill/4348

Sponsor

Name: Sen. Murray, Patty [D-WA]
Party: Democratic • **State:** WA • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Burr, Richard [R-NC]	R · NC		May 26, 2022

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Reported By	Jul 13, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 HR 9329	Related bill	**Nov 18, 2022:** Referred to the Subcommittee on Health.
117 S 5002	Related bill	**Sep 29, 2022:** Held at the desk.
117 S 4535	Related bill	**Jul 14, 2022:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
117 S 4446	Related bill	**Jun 22, 2022:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S3077-3078)
117 S 4378	Related bill	**Jun 13, 2022:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
117 S 4302	Related bill	**May 25, 2022:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709)
117 S 4303	Related bill	**May 25, 2022:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709-2710)
117 S 4288	Related bill	**May 19, 2022:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
117 HR 7679	Related bill	**May 6, 2022:** Referred to the House Committee on Energy and Commerce.
117 S 4152	Related bill	**May 5, 2022:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
117 HR 7640	Related bill	**May 3, 2022:** Referred to the House Committee on Energy and Commerce.
117 HR 7658	Related bill	**May 3, 2022:** Referred to the House Committee on Energy and Commerce.
117 HR 7035	Related bill	**Mar 10, 2022:** Referred to the Subcommittee on Health.
117 S 2952	Related bill	**Oct 7, 2021:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
117 S 2628	Related bill	**Aug 5, 2021:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Jul 13, 2022)

Food and Drug Administration Safety and Landmark Advancements Act of 2022 or the FDASLA Act of 2022

This bill modifies Food and Drug Administration (FDA) authority to collect certain fees. It also expands FDA authority to regulate certain products, including cosmetics.

Among other provisions, the bill

- reauthorizes FDA authority to collect certain fees related to drugs, medical devices, and biosimilar biological products and modifies such fees, including the base fee amounts;
- establishes that certain requirements related to obtaining market approval for a new drug or a biosimilar may be satisfied using alternatives to animal testing, such as in vitro tests;
- authorizes the FDA to require that certain drugs be dispensed with a safe disposal system even if the system does not render a drug nonretrievable (current law requires such a system to render the drug nonretrievable);
- establishes time lines for the FDA to respond to requests to determine whether a drug is a therapeutic equivalent to an approved drug;
- modifies the accelerated process for approving products for a serious or life-threatening disease or condition and establishes an intra-agency coordinating council to ensure consistent and appropriate use of the process;
- requires additional regulation of cosmetics, including by requiring manufacturers to register manufacturing facilities and each cosmetic product with the FDA;
- requires dietary supplement manufacturers to provide to the FDA certain information, including a list of all ingredients, about each dietary supplement that it markets;
- requires an in vitro clinical test to receive FDA premarket approval or a technology certification (or be otherwise exempted) before being introduced into interstate commerce; and
- requires the FDA to temporarily relax certain premarket requirements for a manufacturer that intends to market a new infant formula.

Actions Timeline

- **Jul 13, 2022:** Committee on Health, Education, Labor, and Pensions. Reported by Senator Murray with an amendment in the nature of a substitute. Without written report.
- **Jul 13, 2022:** Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.
- **Jun 14, 2022:** Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
- **May 26, 2022:** Introduced in Senate
- **May 26, 2022:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.